IMUX — Immunic Cashflow Statement
0.000.00%
Last trade - 00:00- $168.30m
- $152.82m
Annual cashflow statement for Immunic, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | 2025 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | -92.9 | -120 | -93.6 | -101 | -97.2 |
| Depreciation | |||||
| Non-Cash Items | 18.9 | 45.7 | 7.63 | 15 | 9.36 |
| Unusual Items | |||||
| Other Non-Cash Items | |||||
| Changes in Working Capital | -9.28 | 9.53 | 15 | 0.564 | 1.84 |
| Change in Prepaid Expenses | |||||
| Change in Accounts Payable | |||||
| Change in Accrued Expenses | |||||
| Change in Other Liabilities | |||||
| Cash from Operating Activities | -83.2 | -65.1 | -70.8 | -84.8 | -85.8 |
| Capital Expenditures | -0.067 | -0.112 | -0.334 | -0.264 | -0.161 |
| Purchase of Fixed Assets | |||||
| Other Investing Cash Flow Items | — | -9.63 | 9.8 | 0 | — |
| Sale/Maturity of Investment | |||||
| Purchase of Investments | |||||
| Cash from Investing Activities | -0.067 | -9.74 | 9.46 | -0.264 | -0.161 |
| Financing Cash Flow Items | — | — | — | 74.3 | — |
| Other Financing Cash Flow | |||||
| Net Issuance / Retirement of Stock | |||||
| Cash from Financing Activities | 42.8 | 95.8 | 1.03 | 74.5 | 65.6 |
| Foreign Exchange Effects | |||||
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | -40.6 | 19.9 | -60.1 | -11 | -20.2 |